We are live on
!
Find out more
BBA
Baker Bros. Advisors Portfolio holdings
AUM
$17.4B
1-Year Est. Return
131.5%
This Fund
S&P 500
This Quarter
Est. Return
+35.46%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.1B
AUM Growth
+$3.24B
(+23%)
Cap. Flow
+$452M
Cap. Flow
% of AUM
2.65%
Top 10 Holdings %
Top 10 Hldgs %
74.38%
Holding
100
New
9
Increased
23
Reduced
7
Closed
14
Top Buys
| 1 |
Kymera Therapeutics
KYMR
|
+$135M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$92.2M |
| 3 |
Praxis Precision Medicines
PRAX
|
+$81.4M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
+$60.9M |
| 5 |
Alkermes
ALKS
|
+$57.5M |
Top Sells
| 1 |
MRUS
Merus
MRUS
|
+$54.1M |
| 2 |
Intellia Therapeutics
NTLA
|
+$47.4M |
| 3 |
Stoke Therapeutics
STOK
|
+$39M |
| 4 |
RNAM
Avidity Biosciences
RNAM
|
+$27.2M |
| 5 |
Vaxcyte
PCVX
|
+$23.1M |
Sector Composition
| 1 | Healthcare | 99.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Incyte
INCY
$22.9B
| $3.04B | 17.78% |
30,743,991
+328
| +0% | +$31.7K |
|
|
ONC
2
BeOne Medicines Ltd
ONC
$31.8B
| $2.67B | 15.65% |
8,799,053
| – | – |
|
3
Madrigal Pharmaceuticals
MDGL
$12.4B
| $1.25B | 7.3% |
2,141,701
| – | – |
|
4
Insmed
INSM
$23.8B
| $1.15B | 6.72% |
6,592,746
-110,738
| -2% | -$20.2M |
|
5
Acadia Pharmaceuticals
ACAD
$4.38B
| $1.15B | 6.71% |
42,896,690
| – | – |
|
6
Celcuity
CELC
$5.38B
| $790M | 4.62% |
7,915,792
| – | – |
|
7
Revolution Medicines
RVMD
$39.3B
| $753M | 4.41% |
9,455,357
| – | – |
|
|
8
Kymera Therapeutics
KYMR
$9.28B
| $674M | 3.94% |
8,657,242
+2,005,813
| +30% | +$135M |
|
9
Summit Therapeutics
SMMT
$12B
| $636M | 3.73% |
36,391,063
+2,668,089
| +8% | +$50.2M |
|
10
Rhythm Pharmaceuticals
RYTM
$7.5B
| $600M | 3.51% |
5,604,483
| – | – |
|
11
Kodiak Sciences
KOD
$2.7B
| $557M | 3.26% |
19,919,186
+2,608,696
| +15% | +$53.4M |
|
|
12
Praxis Precision Medicines
PRAX
$9.1B
| $332M | 1.94% |
1,126,488
+437,000
| +63% | +$81.4M |
|
|
13
Alkermes
ALKS
$8.51B
| $280M | 1.64% |
10,012,267
+1,920,916
| +24% | +$57.5M |
|
|
GRAL
14
GRAIL Inc
GRAL
$3.12B
| $178M | 1.05% |
2,085,333
+455,208
| +28% | +$39.3M |
|
15
Edgewise Therapeutics
EWTX
$4.3B
| $163M | 0.96% |
6,575,940
-730,000
| -10% | -$14.7M |
|
16
Arrowhead Research
ARWR
$10.2B
| $144M | 0.85% |
2,175,645
+504,883
| +30% | +$24.7M |
|
|
17
Ionis Pharmaceuticals
IONS
$9.05B
| $142M | 0.83% |
1,791,841
+1,225,043
| +216% | +$92.2M |
|
18
Immunovant
IMVT
$7.96B
| $139M | 0.81% |
5,457,881
| – | – |
|
19
Immatics
IMTX
$1.28B
| $127M | 0.74% |
12,094,094
| – | – |
|
20
IDEAYA Biosciences
IDYA
$3.52B
| $125M | 0.73% |
3,618,826
+343,382
| +10% | +$10.9M |
|
21
Roivant Sciences
ROIV
$25.1B
| $121M | 0.71% |
5,555,017
+1,787,244
| +47% | +$35.3M |
|
|
ABVX
22
Abivax
ABVX
$11.8B
| $118M | 0.69% |
875,796
| – | – |
|
23
Kiniksa Pharmaceuticals
KNSA
$4.8B
| $117M | 0.68% |
2,826,246
+1,577
| +0.1% | +$63.3K |
|
24
Replimune Group
REPL
$824M
| $107M | 0.63% |
11,045,336
| – | – |
|
|
25
Stoke Therapeutics
STOK
$1.83B
| $106M | 0.62% |
3,336,697
-1,297,141
| -28% | -$39M |
|
Similar funds
MCM
ASRS
PP
CS
SFA
VMPIC
LA
BCIM